{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:23:37Z","timestamp":1790717017139,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Nanjing Health Technology Development","award":["ZKX21016"],"award-info":[{"award-number":["ZKX21016"]}]},{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2021-LCYJ-PY-37"],"award-info":[{"award-number":["2021-LCYJ-PY-37"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2022-JCYJ-QP-04"],"award-info":[{"award-number":["2022-JCYJ-QP-04"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2021-LCYJ-DBZ-02"],"award-info":[{"award-number":["2021-LCYJ-DBZ-02"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019155","name":"Nanjing Drum Tower Hospital","doi-asserted-by":"publisher","award":["2022-YXZX-MY-02"],"award-info":[{"award-number":["2022-YXZX-MY-02"]}],"id":[{"id":"10.13039\/501100019155","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Medical Innovation Team","award":["CXTDA2017041"],"award-info":[{"award-number":["CXTDA2017041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s10067-025-07583-w","type":"journal-article","created":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:42:29Z","timestamp":1754109749000},"page":"3591-3603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Treatment effectiveness of hydroxychloroquine in patients with primary Sj\u00f6gren\u2019s syndrome: a real-world Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Kexin","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangcai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0698-056X","authenticated-orcid":false,"given":"Wei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,2]]},"reference":[{"issue":"3","key":"7583_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41584-023-01057-6","volume":"20","author":"M Beydon","year":"2024","unstructured":"Beydon M, McCoy S, Nguyen Y, Sumida T, Mariette X, Seror R (2024) Epidemiology of Sj\u00f6gren syndrome. Nat Rev Rheumatol 20(3):158\u2013169. https:\/\/doi.org\/10.1038\/s41584-023-01057-6","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"7583_CR2","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","volume":"74","author":"B Qin","year":"2015","unstructured":"Qin B, Wang J, Yang Z et al (2015) Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983\u20131989. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205375","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7583_CR3","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette X, Criswell LA (2018) Primary Sj\u00f6gren\u2019s syndrome. N Engl J Med 378(10):931\u2013939. https:\/\/doi.org\/10.1056\/NEJMcp1702514","journal-title":"N Engl J Med"},{"issue":"6","key":"7583_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror R, Ravaud P, Bowman SJ et al (2010) EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 69(6):1103\u20131109. https:\/\/doi.org\/10.1136\/ard.2009.110619","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7583_CR5","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/ard.2010.143743","volume":"70","author":"R Seror","year":"2011","unstructured":"Seror R, Ravaud P, Mariette X et al (2011) EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 70(6):968\u2013972. https:\/\/doi.org\/10.1136\/ard.2010.143743","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7583_CR6","doi-asserted-by":"publisher","first-page":"e553","DOI":"10.1016\/s2665-9913(21)00122-3","volume":"3","author":"S Arends","year":"2021","unstructured":"Arends S, de Wolff L, van Nimwegen JF et al (2021) Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol 3(8):e553\u2013e562. https:\/\/doi.org\/10.1016\/s2665-9913(21)00122-3","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"7583_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","volume":"79","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S et al (2020) EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis 79(1):3\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216114","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7583_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41584-021-00634-x","volume":"17","author":"R Seror","year":"2021","unstructured":"Seror R, Nocturne G, Mariette X (2021) Current and future therapies for primary Sj\u00f6gren syndrome. Nat Rev Rheumatol 17(8):475\u2013486. https:\/\/doi.org\/10.1038\/s41584-021-00634-x","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"7583_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/s2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, Hoyles RK, Parfrey H, Renzoni EA, Kokosi M, Wells AU, Ashby D, Szigeti M, Molyneaux PL (2023) Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med 11(1):45\u201354. https:\/\/doi.org\/10.1016\/s2213-2600(22)00359-9","journal-title":"Lancet Respir Med"},{"key":"7583_CR10","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.eclinm.2022.101777","volume":"56","author":"Y Wang","year":"2023","unstructured":"Wang Y, Sheng L, Han F, Guo Q, Zhang Z, Hou Y, Feng Q, Zhou H, Ji X, Peng J, Hou M, Xu M (2023) Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: a systematic review and network meta-analysis. EClinicalMedicine 56:101777. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101777","journal-title":"EClinicalMedicine"},{"key":"7583_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110716","volume":"123","author":"F Sun","year":"2023","unstructured":"Sun F, Tang Q, Cheng W, Xie X, Li F, Chen J (2023) Characteristics and treatment responses of immune thrombocytopenia in patients with primary Sj\u00f6gren syndrome. Int Immunopharmacol 123:110716. https:\/\/doi.org\/10.1016\/j.intimp.2023.110716","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"7583_CR12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"key":"7583_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107452","volume":"207","author":"L Zhang","year":"2020","unstructured":"Zhang L, Wei W (2020) Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony. Pharmacol Ther 207:107452. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107452","journal-title":"Pharmacol Ther"},{"key":"7583_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1282610","volume":"14","author":"Y Shan","year":"2023","unstructured":"Shan Y, Zhao J, Wei K, Jiang P, Xu L, Chang C, Xu L, Shi Y, Zheng Y, Bian Y, Zhou M, Schrodi SJ, Guo S, He D (2023) A comprehensive review of Tripterygium wilfordii Hook. f. in the treatment of rheumatic and autoimmune diseases: bioactive compounds, mechanisms of action, and future directions. Front Pharmacol 14:1282610. https:\/\/doi.org\/10.3389\/fphar.2023.1282610","journal-title":"Front Pharmacol"},{"issue":"1","key":"7583_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","volume":"59","author":"ILA Bodewes","year":"2020","unstructured":"Bodewes ILA, Gottenberg JE, van Helden-Meeuwsen CG, Mariette X, Versnel MA (2020) Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren\u2019s syndrome in the JOQUER randomized trial. Rheumatology (Oxford) 59(1):107\u2013111. https:\/\/doi.org\/10.1093\/rheumatology\/kez242","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"7583_CR16","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s10787-021-00887-8","volume":"29","author":"D Eryavuz Onmaz","year":"2021","unstructured":"Eryavuz Onmaz D, Tezcan D, Abusoglu S et al (2021) Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. Inflammopharmacology 29(6):1795\u20131805. https:\/\/doi.org\/10.1007\/s10787-021-00887-8","journal-title":"Inflammopharmacology"},{"key":"7583_CR17","doi-asserted-by":"publisher","unstructured":"Yang DH, Wang YH, Pan LF, Wei JC (2020) Cardiovascular protection of Hydroxychloroquine in patients with Sj\u00f6gren's syndrome. J Clin Med 9(11). https:\/\/doi.org\/10.3390\/jcm9113469","DOI":"10.3390\/jcm9113469"},{"issue":"10","key":"7583_CR18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/qjmed\/hcz112","volume":"112","author":"TH Chen","year":"2019","unstructured":"Chen TH, Lai TY, Wang YH, Chiou JY, Hung YM, Wei JC (2019) Hydroxychloroquine was associated with reduced risk of new-onset diabetes mellitus in patients with Sj\u00f6gren syndrome. QJM 112(10):757\u2013762. https:\/\/doi.org\/10.1093\/qjmed\/hcz112","journal-title":"QJM"},{"issue":"11","key":"7583_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111352","volume":"40","author":"X Wang","year":"2022","unstructured":"Wang X, Pang K, Wang J et al (2022) Microbiota dysbiosis in primary Sj\u00f6gren\u2019s syndrome and the ameliorative effect of hydroxychloroquine. Cell Rep 40(11):111352. https:\/\/doi.org\/10.1016\/j.celrep.2022.111352","journal-title":"Cell Rep"},{"issue":"7","key":"7583_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","volume":"31","author":"CH Yoon","year":"2016","unstructured":"Yoon CH, Lee HJ, Lee EY et al (2016) Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren\u2019s syndrome: a double-blind randomized control study. J Korean Med Sci 31(7):1127\u20131135. https:\/\/doi.org\/10.3346\/jkms.2016.31.7.1127","journal-title":"J Korean Med Sci"},{"issue":"5","key":"7583_CR21","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/s2665-9913(20)30057-6","volume":"2","author":"EHM van der Heijden","year":"2020","unstructured":"van der Heijden EHM, Blokland SLM, Hillen MR et al (2020) Leflunomide-hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. Lancet Rheumatol 2(5):e260\u2013e269. https:\/\/doi.org\/10.1016\/s2665-9913(20)30057-6","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"7583_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/annrheumdis-2016-210571","volume":"76","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R et al (2017) 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76(1):9\u201316. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210571","journal-title":"Ann Rheum Dis"},{"key":"7583_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.693796","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang T, Guo Z et al (2021) The efficiency of hydroxychloroquine for the treatment of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Front Pharmacol 12:693796. https:\/\/doi.org\/10.3389\/fphar.2021.693796","journal-title":"Front Pharmacol"},{"issue":"1","key":"7583_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","volume":"18","author":"A Mirouse","year":"2019","unstructured":"Mirouse A, Seror R, Vicaut E et al (2019) Arthritis in primary Sj\u00f6gren\u2019s syndrome: characteristics, outcome and treatment from French multicenter retrospective study. Autoimmun Rev 18(1):9\u201314. https:\/\/doi.org\/10.1016\/j.autrev.2018.06.015","journal-title":"Autoimmun Rev"},{"issue":"10","key":"7583_CR25","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/1346-8138.16045","volume":"48","author":"H Arakawa","year":"2021","unstructured":"Arakawa H, Tanese K, Tanaka R et al (2021) Efficacy of hydroxychloroquine for treating annular erythema associated with Sj\u00f6gren\u2019s syndrome. J Dermatol 48(10):1526\u20131532. https:\/\/doi.org\/10.1111\/1346-8138.16045","journal-title":"J Dermatol"},{"key":"7583_CR26","unstructured":"Hern\u00e1ndez-Molina G, Valim V, Secco A et al (2018) Do antimalarials protect against damage accrual in primary Sj\u00f6gren\u2019s syndrome? Results from a Latin-American retrospective cohort. Clin Exp Rheumatol 36 Suppl 112(3):182\u2013185"},{"issue":"3","key":"7583_CR27","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.2014.7682","volume":"312","author":"JE Gottenberg","year":"2014","unstructured":"Gottenberg JE, Ravaud P, Pu\u00e9chal X et al (2014) Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomized clinical trial. JAMA 312(3):249\u2013258. https:\/\/doi.org\/10.1001\/jama.2014.7682","journal-title":"JAMA"},{"issue":"1","key":"7583_CR28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tripleo.2010.02.032","volume":"110","author":"H Cankaya","year":"2010","unstructured":"Cankaya H, Alp\u00f6z E, Karabulut G, G\u00fcneri P, Boyacioglu H, Kabasakal Y (2010) Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sj\u00f6gren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110(1):62\u201367. https:\/\/doi.org\/10.1016\/j.tripleo.2010.02.032","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"7583_CR29","doi-asserted-by":"publisher","unstructured":"Dima A, Jurcut C, Chasset F, Felten R, Arnaud L (2022) Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 14:1759720x211073001. https:\/\/doi.org\/10.1177\/1759720x211073001","DOI":"10.1177\/1759720x211073001"},{"issue":"1","key":"7583_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","volume":"13","author":"M Petri","year":"2011","unstructured":"Petri M (2011) Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 13(1):77\u201380. https:\/\/doi.org\/10.1007\/s11926-010-0141-y","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"7583_CR31","first-page":"661","volume":"20","author":"HN Hodis","year":"1993","unstructured":"Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH (1993) The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 20(4):661\u2013665","journal-title":"J Rheumatol"},{"issue":"1","key":"7583_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/1756-185x.13159","volume":"21","author":"H Babary","year":"2018","unstructured":"Babary H, Liu X, Ayatollahi Y et al (2018) Favorable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Int J Rheum Dis 21(1):84\u201392. https:\/\/doi.org\/10.1111\/1756-185x.13159","journal-title":"Int J Rheum Dis"},{"key":"7583_CR33","doi-asserted-by":"publisher","unstructured":"Feng Z, Zhang BQ, Zhu YM et al (2019) The effectiveness and safety of total glucosides of paeony in primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis. Front Pharmacol 10:550. https:\/\/doi.org\/10.3389\/fphar.2019.00550","DOI":"10.3389\/fphar.2019.00550"},{"issue":"3","key":"7583_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155\u2013166. https:\/\/doi.org\/10.1038\/s41584-020-0372-x","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"7583_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M (2020) Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med 12(8):e12476. https:\/\/doi.org\/10.15252\/emmm.202012476","journal-title":"EMBO Mol Med"},{"issue":"4","key":"7583_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/1744666x.2023.2294938","volume":"20","author":"D Paredes-Ruiz","year":"2024","unstructured":"Paredes-Ruiz D, Martin-Iglesias D, Ruiz-Irastorza G (2024) Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus. Expert Rev Clin Immunol 20(4):359\u2013373. https:\/\/doi.org\/10.1080\/1744666x.2023.2294938","journal-title":"Expert Rev Clin Immunol"},{"issue":"10","key":"7583_CR37","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1002\/acr.25381","volume":"76","author":"R Jacobson","year":"2024","unstructured":"Jacobson R, Goldman D, Fava A, Magder L, Petri M (2024) Hydroxychloroquine improves low complement levels. Arthritis Care Res (Hoboken) 76(10):1396\u20131399. https:\/\/doi.org\/10.1002\/acr.25381","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"7583_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110848","volume":"132","author":"J Han","year":"2020","unstructured":"Han J, Li X, Luo X, He J, Huang X, Zhou Q, Han Y, Jie H, Zhuang J, Li Y, Yang F, Zhai Z, Wu S, He Y, Yang B, Sun E (2020) The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: inhibition of dendritic cell functions via Toll like receptor 9 signaling. Biomed Pharmacother 132:110848. https:\/\/doi.org\/10.1016\/j.biopha.2020.110848","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"7583_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","volume":"76","author":"P Izmirly","year":"2020","unstructured":"Izmirly P, Kim M, Friedman DM et al (2020) Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA\/Ro-positive mothers. J Am Coll Cardiol 76(3):292\u2013302. https:\/\/doi.org\/10.1016\/j.jacc.2020.05.045","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7583_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/ard.58.4.253","volume":"58","author":"M Tishler","year":"1999","unstructured":"Tishler M, Yaron I, Shirazi I, Yaron M (1999) Hydroxychloroquine treatment for primary Sj\u00f6gren\u2019s syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58(4):253\u2013256. https:\/\/doi.org\/10.1136\/ard.58.4.253","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7583_CR41","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1513\/AnnalsATS.202301-053OC","volume":"21","author":"H Barnes","year":"2024","unstructured":"Barnes H, Ghazipura M, Herman D, Macrea M, Knight SL, Silver RM, Montesi SB, Raghu G, Hossain T (2024) Cyclophosphamide in patients with systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis. Ann Am Thorac Soc 21(1):122\u2013135. https:\/\/doi.org\/10.1513\/AnnalsATS.202301-053OC","journal-title":"Ann Am Thorac Soc"},{"key":"7583_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2018.07.003","volume":"195","author":"M Torigoe","year":"2018","unstructured":"Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y (2018) Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol 195:1\u20137. https:\/\/doi.org\/10.1016\/j.clim.2018.07.003","journal-title":"Clin Immunol"},{"issue":"6","key":"7583_CR43","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3899\/jrheum.200726","volume":"48","author":"WM Lambers","year":"2021","unstructured":"Lambers WM, Westra J, Bootsma H, de Leeuw K (2021) Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol 48(6):847\u2013851. https:\/\/doi.org\/10.3899\/jrheum.200726","journal-title":"J Rheumatol"},{"issue":"2","key":"7583_CR44","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","volume":"42","author":"I Ben-Zvi","year":"2012","unstructured":"Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y (2012) Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol 42(2):145\u2013153. https:\/\/doi.org\/10.1007\/s12016-010-8243-x","journal-title":"Clin Rev Allergy Immunol"},{"key":"7583_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jconrel.2016.01.056","volume":"225","author":"M Guada","year":"2016","unstructured":"Guada M, Beloqui A, Kumar MN, Pr\u00e9at V, Dios-Vi\u00e9itez Mdel C, Blanco-Prieto MJ (2016) Reformulating cyclosporine A (CsA): more than just a life cycle management strategy. J Control Release 225:269\u2013282. https:\/\/doi.org\/10.1016\/j.jconrel.2016.01.056","journal-title":"J Control Release"},{"issue":"8","key":"7583_CR46","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s00296-010-1415-4","volume":"31","author":"S Yavuz","year":"2011","unstructured":"Yavuz S, Asfuro\u011flu E, Bicakcigil M, Toker E (2011) Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren\u2019s syndrome. Rheumatol Int 31(8):1045\u20131049. https:\/\/doi.org\/10.1007\/s00296-010-1415-4","journal-title":"Rheumatol Int"},{"issue":"4","key":"7583_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/art.40018","volume":"69","author":"N Yokogawa","year":"2017","unstructured":"Yokogawa N, Eto H, Tanikawa A et al (2017) Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol 69(4):791\u2013799. https:\/\/doi.org\/10.1002\/art.40018","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"7583_CR48","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/ard.60.5.514","volume":"60","author":"WU Kim","year":"2001","unstructured":"Kim WU, Seo YI, Park SH et al (2001) Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. Ann Rheum Dis 60(5):514\u2013517. https:\/\/doi.org\/10.1136\/ard.60.5.514","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7583_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69(1):20\u201328. https:\/\/doi.org\/10.1136\/ard.2008.101766","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7583_CR50","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","volume":"41","author":"C Chatre","year":"2018","unstructured":"Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM (2018) Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 41(10):919\u2013931. https:\/\/doi.org\/10.1007\/s40264-018-0689-4","journal-title":"Drug Saf"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07583-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:50:10Z","timestamp":1756453810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,2]]},"references-count":50,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["7583"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07583-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,2]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}